Pharming Group N.V. Files 6-K with October Press Release

Ticker: PHAR · Form: 6-K · Filed: 2025-10-22T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, sec-form-6k, press-release

TL;DR

Pharming Group N.V. (PHAR) filed a 6-K on 10/22/25, including a press release from 10/20/25. Standard update.

AI Summary

Pharming Group N.V. filed a Form 6-K on October 22, 2025, furnishing a press release dated October 20, 2025. The filing is related to the month of October 2025 and is submitted under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The company's principal executive offices are located at Darwinweg 24, 2333 CR Leiden, The Netherlands.

Why It Matters

This filing provides an update from Pharming Group N.V. to the SEC, indicating ongoing corporate communications and regulatory compliance for the period ending October 2025.

Risk Assessment

Risk Level: low — This filing is a routine report of foreign private issuer and does not contain significant new financial or operational information that would immediately impact risk.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose is to report information that Pharming Group N.V. has made or will make public, is required to or has agreed to file with the SEC, and is not otherwise required to file on the Form 20-F.

What specific document is furnished as Exhibit 99.1?

Exhibit 99.1 is a press release of Pharming Group N.V. dated October 20, 2025.

When was Pharming Group N.V. incorporated or organized?

The filing does not explicitly state the incorporation date, but it indicates the State of Incorporation is P7 and the Fiscal Year End is 1231.

What is the business address of Pharming Group N.V.?

The business address is Darwinweg 24, 2333 CR Leiden, The Netherlands.

Under which rules is this Form 6-K filed?

This Form 6-K is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

From the Filing

0001828316-25-000047.txt : 20251022 0001828316-25-000047.hdr.sgml : 20251022 20251022093658 ACCESSION NUMBER: 0001828316-25-000047 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20251020 FILED AS OF DATE: 20251022 DATE AS OF CHANGE: 20251022 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 251408905 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 6-K 1 pharminggroupannouncespres.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated October 20, 2025. EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By: /s/ Fabrice Chouraqui Name: Fabrice Chouraqui Title: CEO Date: October 20, 2025 Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that 12 abstracts have been accepted for presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting taking place in Orlando, Florida on November 6-10. Five posters will present positive new clinical, economic, and comparative data for RUCONEST® (recombinant C1 esterase inhibitor) and its role in on-demand hereditary angioedema (HAE) treatment. Seven posters will highlight new evidence on the real-world effectiveness of Joenja® (leniolisib), including additional results from the Phase III pediatric trial, as well as advancing understanding of the pediatric and caregiver burden in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS). Anurag Relan, Chief Medical Officer of Pharming, commented: “We are proud that our scientific contributions in both hereditary angioedema (HAE) and activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) have been recognized with a significant number of abstract acceptances at this year’s ACAAI. The work underscores the rigor of our research and our commitment to advancing patient care. We look forward to the new data being presented to the medical community during the meet

View on Read The Filing